Oncology

pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights   May Highlights: 8 products completed CADTH review 5 products initiated pCPA negotiations 0 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation.  No negotiations were completed or closed for the first … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): April 2020 Trends and Insights   April Highlights: 6 products completed CADTH review 4 products initiated pCPA negotiations 11 negotiations were completed with an LOI 2 negotiations were closed without an LOI 2 files were closed without negotiation In keeping with pCPA’s communication to industry associations, early trends into their management of files during the challenges associated with COVID indicate that initial priority has been on … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks. Highlights of the pCPA activity in March are: 5 products completed CADTH review, for a total of 16 files under consideration; 2 products initiated pCPA negotiations, for a total of 29 … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights   Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations.  Highlights … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include: ● 2 products completed CADTH review, for a total of 9 files under consideration; ● 4 products initiated pCPA negotiations, for a total of 34 active negotiations; ● 2 negotiations completed for a total of 297 completed negotiations; ● … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations.  Highlights since the last update include: 3 products completed CADTH review, for a total of 10 files under consideration; 0 products initiated pCPA negotiations, for a total of 32 active negotiations; 1 negotiation completed for a total of 295 completed negotiations; 1 negotiation closed, for … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): November 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the November 30, 2019 status of brand negotiations.  Highlights since the last update include: 6 products completed CADTH review, for a total of 9 files under consideration; 4 products initiated pCPA negotiations, for a total of 34 active negotiations; 12 negotiations completed for a total of 294 completed negotiations; No negotiations closed, for … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): October 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the October 31, 2019 status of brand negotiations.  Highlights since the last update include: 4 products completed CADTH review, for a total of 7 files under consideration; 2 products initiated pCPA negotiations, for a total of 42 active negotiations; 6 negotiations completed for a total of 282 completed negotiations; 2 negotiation closed, for … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations.  Highlights since the last update include: 4 products completed CADTH review, for a total of 6 files under consideration; 8 products initiated pCPA negotiations, for a total of 48 active negotiations; 6 negotiations completed for a total of 276 completed negotiations; 1 negotiation closed, for … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): August 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the August 31, 2019 status of brand negotiations.  Highlights since the last update include: 5 products completed CADTH review, for a total of 13 files under consideration; 8 products initiated pCPA negotiations, for a total of 47 active negotiations; 7 negotiations completed for a total of 270 completed negotiations; 1 negotiation closed, for … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): July 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of July 31, 2019. Highlights since the last update include: 5 products completed CADTH review, for a total of 12 files under consideration; 7 products initiated pCPA negotiations, for a total of 47 active negotiations; 6 negotiations completed for a total of 263 completed negotiations; 3 negotiations … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): June 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of June 30, 2019. Highlights since the last update include: 6 products completed CADTH review, for a total of 15 files under consideration; 9 products initiated pCPA negotiations, for a total of 49 active negotiations; 4 negotiations completed for a total of 257 completed negotiations; 3 negotiations … Read More →

pan-Canadian Pharmaceutical Alliance (pCPA): May 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of May 31, 2019. Highlights since the last update include: 2 negotiations completed for a total of 253 completed negotiations; 2 negotiations closed, for a total of 37 closed negotiations; 1 file closed without negotiations, for a total of 65 declined negotiations; 10 products completed CADTH review, … Read More →

CAPT Conference Workshop: Defining “Decision Grade” Real World Evidence (RWE) and its Role in the Canadian Context: A Design Sprint   On Sunday October 21, 2018, the Canadian Association of Population Therapeutics (CAPT) hosted a full day workshop to discuss recent advances in the dialogue on RWE in Canada from a Regulatory, HTA and Reimbursement perspective. The day was attended by participants invited from various stakeholder groups including Health Canada, … Read More →